Research and Markets: Epilepsy Global Clinical Trials Review, H2, 2012

<0> Research and Markets: Epilepsy Global Clinical Trials Review, H2, 2012 </0>

<0> Research and MarketsLaura Wood, Senior Manager.U.S. Fax: 646-607-1907Fax (outside U.S.): +353-1-481-1716Sector: </0>

() has announced the addition of GlobalData's new report "Epilepsy Global Clinical Trials Review, H2, 2012" to their offering.

Our clinical trial report, Epilepsy Global Clinical Trials Review, H2, 2012" provides data on the Epilepsy clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Epilepsy. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Epilepsy. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by Our team of industry experts.

Scope

- Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations

- Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type

- Listings of discontinued trials (suspended, withdrawn and terminated)

Reasons to buy

- Understand the dynamics of a particular indication in a condensed manner

- Abridged view of the performance of the trials in terms of their status, recruitment, location, sponsor type and many more

- Obtain discontinued trial listing for trials across the globe

- Espy the commercial landscape of the major Universities / Institutes / Hospitals or Companies

For more information visit

Source: GlobalData

Suggested Articles

GlaxoSmithKline, its agency McCann Health, and their "Breath of LIfe" smartphone app took the Grand Prix in pharma last night at Cannes Lions Health.

P&G, the packaged goods giant that bought Merck KgAA’s consumer unit, is out in force at Lions Health. Is that a message for rivals?

Jazz Pharma's next drug launch is set for early July after a DEA scheduling for sleepiness drug Sunosi.